论文部分内容阅读
目的探究艾迪注射液联合PD方案(培美曲塞PEM+顺铂DDP)治疗晚期肺腺癌的疗效。方法选取我院已病理确诊的80例晚期肺腺癌患者,随机分为观察组(40例,艾迪注射液+PD方案治疗)和对照组(40例,PD方案治疗)。结果观察组与对照组治疗有效率分别为32.5%,25.0%,差异无统计学意义(P>0.05),而观察组临床获益率(95.0%)明显高于对照组(75.0%),差异有统计学意义(P<0.05);观察组血小板减少的发生率显著低于对照组,差异有统计学意义(P<0.05);观察组生活质量改善率60.0%,显著高于对照组32.5%,差异有统计学意义(P<0.05);观察组体重“上升”、“下降”差异均有统计学意义(P<0.05)。结论艾迪注射液联合PD方案能提高晚期肺腺癌患者化疗疗效、降低化疗毒性反应,促进体重增加,改善患者生活质量,值得临床参考应用。
Objective To investigate the curative effect of Aidi injection combined with PD regimen (pemetrexed PEM + cisplatin DDP) in the treatment of advanced lung adenocarcinoma. Methods Eighty patients with advanced lung adenocarcinoma confirmed pathologically in our hospital were randomly divided into observation group (40 cases treated with Aidi Injection + PD) and control group (40 cases treated with PD). Results The effective rates of the observation group and the control group were 32.5% and 25.0%, respectively, with no significant difference (P> 0.05). The clinical benefit rate (95.0%) in the observation group was significantly higher than that in the control group (75.0% (P <0.05). The incidence of thrombocytopenia in the observation group was significantly lower than that in the control group (P <0.05). The improvement rate of the quality of life in the observation group was 60.0%, which was significantly higher than that in the control group (32.5% , The difference was statistically significant (P <0.05). There was significant difference between the observation group’s body weight “rising” and “falling” (P <0.05). Conclusion Aidi injection combined with PD regimen can improve chemotherapy efficacy, reduce chemotherapy toxicity, promote weight gain and improve quality of life of patients with advanced lung adenocarcinoma, which deserves clinical reference.